Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.76 USD
-0.01 (-1.38%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.76 0.00 (-0.03%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
KPTI 0.76 -0.01(-1.38%)
Will KPTI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KPTI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KPTI
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline
KPTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for KPTI
Karyopharm Therapeutics Inc. (KPTI) Q2 2024 Earnings Call Transcript
Karyopharm Therapeutics: A Cautious Hold Amid Steady Performance and Pipeline Uncertainties
Karyopharm price target lowered by $3 at Baird, here's why
Karyopharm Therapeutics (KPTI) Gets a Buy from RBC Capital
Buy Rating Affirmed for Karyopharm Therapeutics Amid Strong Q2 Performance and Positive Xpovio Sales Outlook